Key clinical point:
Major finding: MHC class II genes were down-regulated 200%-1100% after transplant, compared with pretransplant samples.
Study details: Analysis of genetic changes pre- and posttransplant in 15 patients with AML relapse after transplant, 20 patients with relapse after chemotherapy, and 28 patients in a validation sample.
Disclosures: The study was supported by grants to investigators from the National Institutes of Health, Leukemia & Lymphoma Society, and the Barnes-Jewish Hospital Foundation. Dr. Christopher and several coauthors reported receiving grants from the study funders but no other relevant conflicts of interest. Several coauthors reported receiving personal fees and/or research support from industry outside the submitted work.
Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
This Week's Must Reads
Must Reads in ALL
Tisagenlecleucel responses persist at 18 months in r/r B-cell ALL, Grupp SA et al. ASH 2018, Abstract 895
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
CAR T-cell cost effectiveness in ALL, Whittington MD et al. JAMA Pediatr. 2018 Oct 8. doi: 10.1001/jamapediatrics.2018.2530
CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9